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The envelope glycoprotein (Env) of HIV-1 interacts with the clathrin-associated adaptor complex AP-2 during the late phase of the viral
replication cycle. Upon its synthesis, Env, therefore, is retrieved from the cellular surface unless internalization is inhibited by viral Gag. Here
we demonstrate that not only Env, but also HIV-1 Gag, specifically binds to AP-2. Gag–AP-2 association was found to depend on tyrosine
residue 132 and valine residue 135 at the matrix–capsid junction in the Gag polyprotein. Results of a morphological analysis of viral egress
from cells expressing dominant-negative AP-2 suggest an involvement of AP-2 in confining HIV-1 exit to distinct microdomains. Further,
particle release from AP-2-mutant cells was enhanced compared to release from wild-type cells but the infectivity of virus released from these
cells was moderately reduced. Together these data attribute a role to the AP-2 complex in the regulation of HIV-1 assembly/release.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; Gag; Assembly; Release; Adaptor; AP-2Introduction
HIV-1 particles are not shed continuously from infected
cells and virus budding does not take place uniformly all
over the cell. Instead, budding appears to be restricted to
certain membrane domains. Such spatially restricted release
of viral particles is likely to ensure efficient dissemination
within the infected organism. The mechanisms that confine
lentivirus release to distinct areas are not yet understood.
However, viral budding from discrete sites coincides with
the accumulation of the viral components, particularly Gag
and the envelope glycoprotein (Env), in these areas. The
observed non-random localization of the viral structural0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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particle release (e.g., Lodge et al., 1997).
To characterize signals that control the routing of the
structural components of HIV-1, it is necessary to analyze
their trafficking and to investigate how they interact with
elements of the cellular protein sorting machinery.
Previous analyses have allowed to determine sequences
in the cytosolic domain of HIV-1 Env which are crucial
for the interaction with two components of the cellular
sorting machinery. Specifically, it was shown that viral
Env interacts with the clathrin-associated adaptor com-
plexes AP-1 and AP-2 during the late phase of the viral
replication cycle (Berlioz-Torrent et al., 1999; Boge et al.,
1998; Ohno et al., 1997; Wyss et al., 2001). AP-2, a
heterotetrameric complex, recruits membrane proteins into
coated pits via specific interactions of its medium chain
A2 with signals in the cytosolic domains of these proteins
(e.g., Bonifacino and Traub, 2003). Upon its synthesis,
HIV-1 Env therefore is retrieved from the cellular surface05) 190 – 200
Fig. 1. Binding of purified A2 and AP-2 to Gag. (A) HIV-1 Gag protein
organization, potential AP-2 binding sites. (B) Binding of A2 to GST-Gag
fusion proteins. Gag wt or Gag deletion mutants were used in a pulldown
assay with 35S-labeled A2 subunit of AP-2. Two sections of the same gel are
shown (same exposure time). (C) Binding of GST-Gag fusion proteins to
either purified AP-2 complex or to A2 subunit. GST-Gag fusion proteins
were coupled to SPR sensor chips via an anti-GST antibody at equal
densities. Purified adaptor complexes or the purified adaptor subunit A2
were passed over the Gag-derived chip surfaces. Sensograms of Gag–
adaptor/A2 interaction recorded in real time were used to calculate ka (on
rate), kd (off rate), KD (ka / kd). Shown is the binding of AP-2 injected at a
concentration of 2 AM. The kinetic data of all Gag variants tested are
summarized in Table 1.
M. Batonick et al. / Virology 342 (2005) 190–200 191unless such internalization is inhibited by viral Gag (Egan
et al., 1996). It has been suggested that the endocytosis of
newly synthesized Env helps protect the infected cells
from immune attack (Fultz et al., 2001; Marsh and
Pelchen-Matthews, 2000). In addition, it is now known
that HIV-1 exits directly through late endosomal mem-
branes in macrophages and that it can egress through
membranes belonging to, or derived from, the endocytic
compartment in other cell types (Nguyen et al., 2003;
Nydegger et al., 2003; Ono and Freed, 2004; Pelchen-
Matthews et al., 2003; Raposo et al., 2002; Sherer et al.,
2003; von Schwedler et al., 2003). Hence, interactions of
viral components with the cellular internalization machi-
nery, which provides guidance into the endocytic pathway,
may assist in targeting the formation of HIV-1 particles to
these subcellular sites.
Like other retroviral Gag proteins, HIV-1 Gag can
form virus-like particles (VLPs) in the absence of other
viral components and thus directs particle assembly and
release (Swanstrom and Wills, 1997). Efficient release of
retroviruses depends on the presence, within Gag, of a so-
called late (L) domain that recruits the cellular machinery
necessary for viral budding (Freed, 2002; Morita and
Sundquist, 2004). The L domain of HIV-1 is located in p6
at the COOH-terminal region of Gag (Gottlinger et al.,
1991; Huang et al., 1995). It contains two distinct motifs,
a PTAP and an LYPLTSL sequence for the recruitment of
cellular vesiculation machinery, whereas a PPPY motif in
the L domain of other retroviruses appears to be critical
for particle release (Freed, 2002; Morita and Sundquist,
2004). The L domain of equine infectious anemia virus
(EIAV) was reported to be centered at Y23 within p9 of
EIAV Gag (Puffer et al., 1997) and the same Y23 was
shown to be part of a YxxL motif that recruits the A2
subunit of AP-2 (Puffer et al., 1998), suggesting that AP-
2 may contribute to promoting release of this virus.
However, so far no functional data support this hypoth-
esis, whereas results reported by three groups demon-
strated that AIP1/ALIX, a human VPS class E protein,
mediates EIAV L domain function via its recruitment by
the LY23PDL sequence (Martin-Serrano et al., 2003; Strack
et al., 2003; von Schwedler et al., 2003), as predicted
(Vincent et al., 2003).
Here we report that HIV-1 Gag, like EIAV Gag, binds
AP-2. Because AP-2 has been considered a cellular factor
mediating efficient release of EIAV, we tested whether
abrogation of Gag–AP-2 interaction resulted in reduced
particle release. However, we found the opposite: HIV-1
release was enhanced when the Gag–AP-2 association was
interrupted. Interestingly, the subcellular distribution of Gag
in cells expressing dominant-negative AP-2 differed mark-
edly from the distribution in AP-2-wild-type cells, implying
that AP-2 plays a role in the late phase of the HIV-1
replication cycle, perhaps by targeting the external and the
internal structural components of this virus to the sites
where particles exit from cells.Results
HIV-1 Gag binds the clathrin-associated adaptor complex
AP-2
Upon its biosynthesis and transport to the cell surface,
HIV-1 Env is rapidly internalized through a specific
interaction with the clathrin-associated adaptor complex
AP-2 (Boge et al., 1998; Marsh and Pelchen-Matthews,
2000; Rowell et al., 1995). As co-expression of HIV-1
Gag reduces the level of Env internalization, Gag was
postulated to compete with the cellular endocytosis
machinery for the acquisition of Env. However, Gag itself
contains six sequences conforming to the AP-2 binding
motifs YxxA (A being a bulky, hydrophobic residue) or
LL (Fig. 1A; for a recent review, see Bonifacino and
Traub, 2003). Fig. 1B, third lane, shows that full-length
Gag, in the context of a GST fusion protein, precipitates
Fig. 2. VLP and of HIV-1 Gag release is increased in AP-2-mutant cells.
(A) Gag-EGFP VLP release in AP-2-wild-type and AP-2-mutant cells. (B)
HIV-1 particle release from AP-2-wild-type and AP-2-mutant cells. 35S-
labeled cells expressing wild-type or mutant AP-2 (Nesterov et al., 1999)
were transfected with either Gag-EGFP expressor plasmids or pNL43 for
the production of either VLPs or the full-length virus. VLPs or viruses (V)
were harvested and Gag was immunoprecipitated from the lysate (L) as
described in Materials and methods and the amounts of released particles
were quantified by phosphoimager. Different sections of the same gel are
shown (same exposure time). The relative amount of released particles was
determined by dividing the amount of Gag-EGFP in released particles by
M. Batonick et al. / Virology 342 (2005) 190–200192the medium chain A2 of AP-2. C-terminal deletion
mutants were engineered such that Gag lacked the
potential AP-2 binding sites at positions 322 and 333
(321 stop), or the potential binding sites downstream of,
and including, 301 (301 stop), 267 (266 stop), or all six
sites (131 stop) (Fig. 1A). Binding to A2 was affected for
the 131 stop mutant in the GST pull-down experiments
but not for the other deletion mutants (Fig. 1B),
suggesting that Y132 might be part of a YxxA motif.
To test the possibility that the sequence Y132PIV135
was involved in Gag–A2 binding, we made mutants with
single amino acid changes at positions 132 through 135. We
also sought to determine the relative affinities for A2 and for
the entire AP-2 complex of the different Gag mutants, as
done previously for HIV-1 Env (Wyss et al., 2001). Gag–
adaptor interactions were thus quantified by surface
plasmon resonance (SPR) analysis, a technique that allows
real-time analysis of A2 or purified adaptor complex
association with GST-Gag that has been coupled to a sensor
chip via an anti-GST antibody. Association and dissociation
curves (Fig. 1C) were determined by adding different
concentrations of A2 or purified AP-2 complex and served
as basis for calculating the kinetic rate constants that are
displayed as relative values in Table 1. This analysis
revealed that residues Y132 and V135 are important for
A2/AP-2 binding, as the relative affinities (KD’s) of the
Y132A and the V135A mutant were indistinguishable from
background values measured for GST. In contrast, binding
of A2/AP-2 to Gag was only marginally affected, if at all,
when Y132 was exchanged for a phenylalanine, if residues
P133 or I134 were replaced by alanine, or if the dileucines
at positions 267, 282, 322, and 333 or the Y302-based motif
were deleted. Overall, the SPR analysis demonstrates that
distinct residues within the YxxA motif at the MA-CA
junction are critical for Gag–A2/AP-2 interaction.Table 1














GST NB NB NB NB NB NB
WT 2.7  103 4.0  103 1.5 2.5  103 5.5  103 2.2
Y132A NB NB NB NB NB NB
Y132F 2.5  103 4.0  103 1.6 2.1  103 5.0  103 2.4
P133A 3.3  103 3.9  103 1.2 2.8  103 5.5  103 2.0
I134A 3.3  103 3.8  103 1.4 2.5  103 5.5  103 2.2
V135A NB NB NB NB NB NB
131 stop NB NB NB NB NB NB
266 stop 2.9  103 4.0  103 1.4 2.4  103 5.1  103 2.1
301 stop 2.8  103 3.9  103 1.4 2.5  103 5.5  103 2.2
321 stop 2.9  103 4.0  103 1.4 2.4  103 5.2  103 2.2
Binding of AP-2 (A) or A2 (B) was monitored in real time with an SPR-
based biosensor as outlined in Materials and methods. At least 4
concentrations were passed over the GST-Gag derivatized surfaces. The
resulting sensorgrams were then used to calculate the rate constants of the
interaction assuming a 1:1 type of interaction. NB: binding indistinguish-
able from background.
the amount of total Gag-EGFP (i.e., cell-associated and released Gag-EGFP
together). Data are representative of at least six experiments. Error bars
represent standard error of mean (SEM).Disruption of Gag–AP-2 interaction leads to increased
HIV-1 particle release
A A2 binding site is situated at the center of the EIAV L
domain (Puffer et al., 1998). The AP-2 complex thus had to
be considered a candidate cellular factor that mediates
efficient lentivirus particle release (for a review, e.g., Freed,
2002). Because AP-2 specifically interacts with HIV-1 Gag,
we tested whether Y132 was part of a L domain, i.e.,
whether it was involved in mediating proper HIV-1 particle
release by acting as a receptor for AP-2. We made use of a
HeLa-derived cell line in which the wild-type A2 subunit of
AP-2 can be replaced by mutant A2 that no longer associates
with tyrosine-based internalization motifs (for a description
of this inducible, functional knockout cell line see Nesterov
et al., 1999). AP-2-wild-type and AP-2-mutant cells tran-
siently expressing Gag-EGFP were radiolabeled and the
Fig. 3. Non-conservative mutation of Y132 in Gag leads to increased particle
release. (A) Mutant Gag-EGFP release from wild-type and mutant AP-2
cells. 35S-labeled cells expressing wild-type or mutant AP-2 were transfected
with either wild-type Gag-EGFP or Gag-EGFP with either a non-
conservative (Y132A) or a conservative (Y132F) mutation at position 132.
(B) Release of mutant HIV-1 Gag fromwild-type andmutant AP-2 cells. 35S-
labeled cells expressing wild-type or mutant AP-2 were transfected with
either wild-type pNL43 or pNL43 with a non-conservative (Y132H) or a
conservative (Y132F) mutation in Gag. The relative amount of VLPs or
released virus was determined by dividing the amount of Gag in released
particles by the amount of total Gag (i.e., cell-associated and released Gag
together). Different sections of the same gel are shown (same exposure time).
Data are representative of four experiments. Error bars represent SEM.
Fig. 4. Virus released from AP-2-mutant cells is less infectious and
incorporates less Env than virus released from wild-type cells. (A)
Infectivity of virus released from AP-2-wild-type or AP-2-mutant cells.
Cells expressing either wild-type or mutant AP-2 were transfected with
pNL43. The amount of released virus was quantified by p24 ELISA and
equal amounts were used to infect MAGI cells. Infected MAGI cells were
counted by an unbiased investigator. Data are the means of three
experiments. Error bars represent standard deviation (P value < 0.01).
(B) Env incorporation. AP-2-wild-type and AP-2-mutant cells were
transfected with pNL43. Released virus was harvested and its composition
analyzed as described in Materials and methods. Data are the means of three
experiments. Error bars represent standard deviation (P value < 0.01). The
representative gel shows virus released from AP-2-wild-type cells (left lane)
and released from AP-2-mutant cells (right lane).
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determined by phosphoimager analysis of pelleted VLPs
and immunoprecipitated Gag from cell lysates. As shown in
Fig. 2A, cells expressing non-functional AP-2 released more
than twice as many particles than cells expressing wild-type
AP-2. This inequality was not due to clonal differences
between the cell line expressing wild-type A2 and the line
expressing mutant A2, as both cell lines release virus with
the same efficiency in the uninduced state (data not shown).
To determine whether release of full-length virus (NL-43)
was also enhanced in cells expressing mutant AP-2, the
amounts of shed virions were determined as described
above for the VLPs. Fig. 2B documents that lack of
functional AP-2 in virus-producing cells leads to a threefold
enhancement of viral particle release. Together, theseexperiments suggested that AP-2, rather than promoting
particle release, limits viral egress.
To further confirm that the HIV-1 Gag–AP-2 interaction
is involved in restricting particle release, we analyzed
whether mutations of Y132, one of the residues in Gag that
is critical for Gag–AP-2 interaction (see Fig. 1C, Table 1),
positively affected virus release. Release experiments as
described above were performed using a previously
described mutant virus with a conservative amino acid
exchange at position 132 (Y132F) (Freed et al., 1997) and
another virus from the same laboratory with a non-
conservative mutation (Y132H) which causes a partial
processing defect (see Fig. 3B, middle lanes of both panels).
Fig. 5. Colocalization of Gag and AP-2 in wild-type and AP-2-mutant cells.
(A) AP-2-wild-type cells or (B) AP-2-mutant cells expressing Gag. Cells
expressing Gag were fixed, permeabilized, and stained with antibodies
against p6 and the a-chain of AP-2 and with an anti-mouse secondary
antibody conjugated to AlexaFluor 594 or an anti-rabbit secondary antibody
conjugated to AlexaFluor 488, as described in Materials and methods. The
bottom section of cells is shown. Ten pictures of each situation were taken
and Gag–AP-2 colocalization was quantified using Volocity (Improvision)
colocalization software. Gag colocalization with AP-2 in AP-2-mutant cells
is reduced by 38% as compared to colocalization in wild-type cells
(colocalization in wild-type cells: 20.4%, SD = 2.65; colocalization in
AP-2-mutant cells: 12.5%, SD = 3.98; P value < 0.001).
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affected if Y132 was replaced by either phenylalanine or
alanine. While the release of VLPs (Fig. 3A, left panel) and
virus (Fig. 3B, left panel) was only slightly affected by the
conservative mutation, release of the VLP and of virus
carrying the non-conservative mutation was enhanced at
least twofold and threefold respectively as compared to
wild-type (Figs. 3A and B, respectively), in agreement with
the hypothesis that the Gag–AP-2 interaction contributes to
limiting VLP/virus release from cells. The combination of
mutations in AP-2 and in Gag in the context of the whole
virus but not in the context of Gag-EGFP lead to a further
enhancement of particle release (compare first to second
bars in Figs. 3A and B, right panels).
Lack of functional AP-2 in virus-producing cells affects the
infectivity of HIV-1 particles
To assess whether the enhancement of release affected the
infectivity of the virus, we incubated the indicator cell line
MAGI (Kimpton and Emerman, 1992) with equal amounts of
wild-type virus released from either AP-2-wild-type or AP-2-
mutant cells. Fig. 4A documents that the infectivity of virions
released from AP-2-mutant cells was moderately affected.
Virus produced in AP-2-mutant cells was found to incorpo-
rate less Env than particles produced in wild-type cells
(Fig. 4B), presumably contributing to this reduced infectivity.
The subcellular distribution of viral Gag is altered if
Gag–AP-2 association is disrupted
Because AP-2, like other adaptor complexes, forms only
low-affinity interactions with its cargo (Kirchhausen, 1999),
at any given time only a small percentage of cargo
molecules bind to this adaptor. Consequently, AP-2 inter-
acting proteins do not colocalize extensively with adaptors
and in immunofluorescence studies the patterns for AP-2
and its various ligands typically look quite different.
Nevertheless, when examining AP-2 and Gag localization,
we found that a small fraction of Gag colocalized with AP-2
in cells expressing wild-type A2. Gag–AP-2 colocalization
was reduced by about a third in cells expressing mutant A2
(Fig. 5). More strikingly though, the overall distribution of
viral Gag appeared altered in cells expressing mutant A2
(see below).
As HIV-1 egress normally is confined to distinct spots at
the plasma membrane (e.g., Hermida-Matsumoto and Resh,
2000; Ono et al., 2000; Sandefur et al., 1998), and also
given the altered distribution of Gag in cells expressing
mutant A2 (Fig. 5B), it seemed conceivable that AP-2 limits
the amount of virus release (Figs. 2 and 3) by restricting the
interaction of HIV-1 Gag and the cellular extravesiculation
machinery. As a first step towards analyzing this hypothesis,
we utilized fluorescence microscopy to compare the local-
ization of surface Gag clusters in situations where Gag and
AP-2 are allowed to associate efficiently with the local-ization of Gag in cells where such an interaction was
prohibited either because A2 was mutated or because residue
Y132 in Gag was exchanged for an alanine. To rigorously
quantify the data, an investigator who was unaware of the
nature of the samples scored 100 randomly mixed pictures
of cells (50 each of wild-type and AP-2-mutant cells
combined in a common pool of images). Criteria for the
analysis were the size of Gag clusters and their subcellular
distribution (see legend of Fig. 6 for a description of how
cell phenotypes were scored and the results of this
quantitative analysis). Figs. 6A and B show representative
wild-type AP-2 and mutant AP-2 expressing cells, respec-
tively. While the overall distribution of wild-type and
mutant AP-2 complex was judged to be similar in both cell
types (left panels), HIV-1 Gag-EGFP accumulated more
peripherally and in fewer but larger clusters in cells
expressing non-functional AP-2 adaptor complex (right
panels). To confirm that a lack of Gag–AP-2 interaction
alters the localization of Gag clusters, either Gag Y132A
(Fig. 6C) or Gag Y132F (Fig. 6D) was expressed in AP-2-
wild-type HeLa cells. Similar to the situation shown for
wild-type Gag in AP-2-mutant cells in Fig. 6B, right panel,
Y132A mutant Gag accumulated in fewer but larger
peripheral clusters and also at the outer edge of the cell-
substrate interface. The Y132F mutant showed wild-type
phenotype. Finally, the distribution of Gag Y132A and
Y132F clusters in AP-2-mutant cells was analyzed. Like in
all the previous experiments the investigator scored
M. Batonick et al. / Virology 342 (2005) 190–200 195ungrouped pictures of similarly shaped cells that were part
of a pool containing both AP-2-wild-type or mutant cells
expressing either mutant or wild-type Gag. The distribution
of the mutant Gag surface clusters in AP-2-mutant cells
clearly showed the most pronounced aberration (Fig. 6E).Altogether, these experiments are compatible with the
hypothesis that AP-2, via a specific interaction with HIV-1
Gag, is involved in controlling the subcellular site of virus
release.Discussion
HIV-1 Env interacts with AP-2 during the late phase of
the viral replication cycle. We now show that this cellular
sorting complex also associates with HIV-1 Gag. Based on
the finding that the central motif in the L domain of EIAV
Gag binds AP-2, the possibility that this complex is
involved in promoting lentiviral release had to be consid-
ered. Our data suggest that under the circumstances tested in
this paper, rather than furthering particle release, this
adaptor limits HIV-1 egress.
The cellular internalization machinery recruits cargo for
clathrin coated pits via interactions with adaptors such as
arrestin or AP-2 (for recent reviews, see Bonifacino and
Traub, 2003; Traub, 2003). Cargo typically consists of
integral membrane proteins that are retrieved from the cell
surface. HIV-1 Env, for example, may have evolved to be
retrieved from the cell surface upon synthesis in order to
prevent immune attack (Marsh and Pelchen-Matthews, 2000)
and to prevent fusion of the producer cell and the target cell in
situations where virus is transmitted at the virological
synapse (Johnson and Huber, 2002; Jolly et al., 2004;
Phillips, 1994). Retroviral Gag, however, is not exposed at
the surface. As a peripheral membrane protein, it anchors at
the cytoplasmic side of cellular membranes via a myristic
acid that is post-translationally attached to its N-terminus. We
were surprised, therefore, when we first noticed that full-
length HIV-1 Gag associates with AP-2. However, as
documented now in this report, HIV-1 Gag and AP-2 interact
specifically with each other. The GST pull-down experiments
and the SPR experiments reported in Fig. 1 and in Table 1
demonstrate that residues Y132 and V135 at/near the MA–Fig. 6. Gag-EGFP distribution in wild-type and AP-2-mutant cells
Localization of Gag-EGFP expressed in AP-2-wild-type cells (A) and in
AP-2-mutant cells (B). Localization of Gag-EGFP containing a mutation a
Y132 in AP-2-wild-type cells. Gag-EGFP with a non-conservative mutation
Y132A (C), or a conservative mutation, Y132F (D). AP-2-mutant cells
expressing GagY132A-EGFP (E) or GagY132F-EGFP (F). Cells were fixed
and permeabilized and stained with an anti-a chain antibody (left panels
and with an AlexaFlour 594-conjugated anti-mouse secondary antibody as
described in Materials and methods. Fifty pictures each of secondary mutan
scenarios (B–F) were pooled together with fifty pictures of wild-type
scenario (A) and were analyzed by an investigator unaware of the nature o
the samples. The cells were scored on a scale of 1–5 with 1 displaying the
most wild-type phenotype and 5 displaying the most mutant phenotype with
regard to Gag distribution. The numbers shown are the average of 50 cells
counted, a representative cell is shown for each phenotype: (A) AP-2-wild
type cells/wild-type Gag: 1.8; (B) AP-2-mutant cells/wild-type Gag: 3.2; (C
AP-2-wild-type cells/Y132A mutant Gag: 3.2; (D) AP-2-wild-type cells
Y132F mutant Gag: 1.8; (E) AP-2-mutant cells/Y132A mutant Gag: 4.0; (F
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Together with the finding that the 131 stop mutant no longer
binds A2 and AP-2, these data also strongly suggest that this
association is significant only during the late phase of the
viral replication cycle and not when the virus enters into cells,
as maturation during viral budding cleaves the Gag precursor
between the residues Y132 and P133. As a consequence of
this developmental switch, the N-terminus of the p24 capsid
refolds into a h-hairpin/helix structure (von Schwedler et al.,
1998), thus destroying the AP-2 binding site.
Comparable to our Env-AP-2 and Env-AP-1 studies, we
found that mutations that decrease binding of the A subunit
(A1 or A2) also show lower affinity for the whole complexes
(AP-1 or AP-2). However, compared with our previous
studies, in the current SPR analysis we used a buffer
containing higher salt concentrations because we recently
recognized that such conditions minimize non-specific
protein-protein interactions (Honing et al., 2005). The fact
that affinities of Gag for A2 and AP-2 do exactly parallel
each other provides strong evidence for the importance of
the Y132-centered region for Gag–AP-2 interaction. Still, it
should be pointed out that the SPR method provides
measurements of relative affinities only. It is now well
established that post-translational modifications such as
phosphorylation of the adaptors and interactions of both
cargo and adaptors with other components of the cellular
internalization modulate the adaptor-cargo interaction in
vivo (Conner and Schmid, 2002; Ricotta et al., 2002; for a
review, see Kirchhausen, 1999).
As the sequence Y23PDL that is responsible for EIAV
Gag–AP-2 interaction was shown to be critical for EIAV
release (Puffer et al., 1997, 1998), it seemed conceivable that
AP-2 is a cellular factor mediating L domain function, i.e.,
promoting viral particle release, but so far no functional
studies support that hypothesis. As demonstrated in Figs. 2
and 3, we find that mutations in either AP-2 or HIV-1 Gag
that inhibit their interaction, rather than decreasing viral
budding, lead to increased particle release in HeLa cells. Our
data therefore suggest that AP-2 is involved in restricting
HIV-1 particle release. Nevertheless, the small but still
significant decrease in infectivity of virus released from AP-
2-mutant cells (Fig. 4A), possibly due to reduced Env
incorporation in virus produced in AP-2-mutant cells (Fig.
4B), is also compatible with a potentially positive role for
AP-2 in HIV-1 egress. Interestingly, Lamb and colleagues
recently identified a APxV motif being the center of an L
domain in a paramyxovirus (Schmitt et al., 2005). AIP1/
ALIX apparently is not the partner for that motif. Whether
AP-2 binds to this sequence is currently under investigation
(A. Schmitt and R. Lamb, personal communication).
Consistent with the hypothesis that AP-2 plays a positive
role in virus release, we found that AP-2 is involved in
proper Gag targeting (Figs. 5 and 6). While newly
synthesized wild-type HIV-1 Gag localizes to relatively
small but distinct areas at the surface of HeLa cells (Fig.
6A), compatible with previous reports (Hermida-Matsumotoand Resh, 2000; Ono et al., 2000; Sandefur et al., 1998),
Gag is targeted to fewer but larger and more peripherally
localized zones at the plasma membrane if the Gag–AP-2
interaction is disrupted (Figs. 6B–F). Also, as in the
experiments where we analyzed the effects on particle
egress of mutations in AP-2 and Gag (Fig. 3), we noticed
that the effects on targeting of release were additive, i.e.,
that the distribution of viral budding sites was distorted most
dramatically if Y132A mutant Gag was expressed in AP-2-
mutant cells (Fig. 6E). The findings that the phenotypes of
mutant virus (i.e., its release, as shown in Fig. 3 and Gag
targeting, as documented in Fig. 6) are further enhanced in
AP-2-mutant cells suggest that the exchange of Y132 for an
alanine does not completely abrogate Gag–AP-2 binding in
situ (in cells), or that sequences in Gag other than Y132 or
other cellular or viral components (e.g., Env) contribute to
the Gag–AP-2 interaction and release of virus. Also, note
that binding to A2 of the 131 stop mutant is not completely
abrogated in the GST pull-down experiments (Fig. 1B),
perhaps due to the presence of such hypothetical cellular
factors in the reticulocyte lysate in which A2 was produced.
So far AP-2 is regarded as one key component of receptor
mediated endocytosis linking cargo concentration to the
process of coat formation. Recent evidence suggests that
HIV-1 Gag, if anchored to the membrane via the trans-
membrane and the extracellular domains of a cellular integral
membrane protein, can be retrieved from the plasma mem-
brane (Lindwasser and Resh, 2004). It remains to be analyzed
whether AP-2 contributes to the observed retrieval. Also, the
purpose of such a retrieval of Gag during the HIV-1 assembly/
release process is not immediately evident. HIV-1 and other
viruses may have evolved to have Gag endocytosed in order
to prevent excess budding which could be detrimental to the
health of the producer cells, thus allowing for sustained
shedding of viral particles. Alternatively, such down regu-
lation may be restricted to misfolded and/or mistargeted Gag.
Rather than promoting Gag internalization, the transient
interaction with AP-2 may serve to target Gag, and thus
virus release, to distinct microdomains. Recently published
data suggest that determinants in Gag other than the p6Gag-
localized L domain, which is responsible for the recruitment
of the vesiculation machinery, must exist that assist in
targeting Gag to those sites where morphogenesis takes
place (Ono and Freed, 2004). The Y132-centered motif
would be particularly well suited to serve as a targeting
signal because it is destroyed upon viral budding and thus
inactive in newly infected cells. Based on the findings that
(1) the release of HIV-1 particles is mediated by distinct
components of a cellular outward vesiculation machinery
and (2) not only Gag but also Env interacts with AP-2, it
would appear plausible that the observed Gag–AP-2
interaction assists in targeting Gag to those subcellular
sites, where the vesiculation machinery and viral Env are
hosted. Studies are underway in our laboratory to determine
whether Gag and Env can associate with AP-2 simulta-
neously. Finally, even though Gag and AP-2 also affect each
M. Batonick et al. / Virology 342 (2005) 190–200 197other, it is possible that AP-2 affects HIV-1 release
indirectly, e.g., via an interaction with other cellular proteins
involved in Gag trafficking. This seems all the more likely
given that AP-2 serves as membrane-based hub for many
proteins (e.g., Praefcke et al., 2004).
The current analysis presents a first step only in our
investigation aimed at elucidating AP-2’s function(s) during
HIV-1 assembly and release. However, together with a
recently published study that reports the incorporation of
AP-2 into Moloney murine leukemia virus (Mo-MuLV)
(Wang et al., 2003) and a paper describing competition
between cellular factors involved in inward budding (AP-2)
and outward budding (AIP1/ALIX) (Geminard et al., 2004),
our study also raises the intriguing possibility that retroviral
budding may be controlled by components of the early
endocytic pathway.Materials and methods
Mammalian cell culture, plasmids, and transfections
Wild-type and mutant AP-2 HeLa cells expressing an
inducible A2 subunit (Nesterov et al., 1999) were grown in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen)
supplemented with 10% fetal bovine serum (FBS; Invitro-
gen), 400 Ag/ml G418 (Invitrogen), 100 U/ml penicillin/
streptomycin (Invitrogen), 200 ng/ml puromycin (Sigma),
and 2 Ag/ml tetracycline (Calbiochem). The cells were
planted in either chambered coverslides (Lab-Tek) or T25
flasks, in media without tetracycline, and grown to approx-
imately 90% confluency. The following plasmids were used:
pNL43, pGag-EGFP (Sandefur et al., 1998), and pGagopt
(Rudner et al., 2005). Transfections were performed 3 days
after removal of tetracycline from the media using Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s
protocol. Analysis of cells was done 24 h after transfection
with pGag-EGFP or pGagopt and 48 h after transfection with
pNL43.
Recombinant proteins
All constructs used in the in vitro binding assays
were made by ligation of polymerase chain reaction
(Pwo DNA polymerase; Boehringer Mannheim)-amplified
DNA fragments into pGEX-2TK (Amersham Pharmacia
Biotech). The 5V-primer sequence was the same for all
GST-Gag constructs: 5V-GATGGGTGCGAGAGC-3V. The






The polymerase chain reaction products were phosphory-
lated and inserted into SmaI-linearized pGEX-2TK.Site-directed mutagenesis was performed in the GST
fusion constructs using the Quick ChangeTM system
(Stratagene). The following primer was used: 5V-
CAGGTCAGCCAAAATGCCCCGATCGTGCAGAA-
CATC-3V. The mutations were confirmed by DNA
sequencing.
Binding assay: GST pull-down experiments
GST fusion proteins were produced in Escherichia coli
strain BL21 and purified over glutathione Sepharose 4B
beads (Amersham). Precultures were grown in 100 ml of
LB +Amp overnight at 37 -C. The cultures were diluted
into 700 ml of LB +Amp and protein production was
induced by adding 0.1 mM isopropyl-h-d-thiogalactoside
(IPTG). Purification over glutathione Sepharose 4B beads
was performed according to the manufacturer’s instruc-
tions including a heat shock step with 50 mM Tris–HCl
(pH 7.4), 10 mM MgSO4, and 2 mM ATP for 10 min at
37 -C. Concentration and quality of the fusion proteins
was monitored on an SDS–PAGE gel after staining with
Coomassie blue (Sigma Chemicals) not only after
preparation of the probes but also at the end of each
experiment, after precipitation of A2.
35S-labeled A2 proteins (Boge et al., 1998) were made
by in vitro transcription and translation of the 3M9 A2
plasmid (Ohno et al., 1995) from a T7 promoter using a
TNT kit (Promega), according to the manufacturer’s
protocol. 4 Al of 35S-labeled A2 and equal molar amounts
of GST-fusion proteins were added to beads and
incubated for 1 h at 37 -C. The beads were washed
twice with PBS then heated in sample buffer for 5 min at
100 -C. The precipitates were resolved by SDS–PAGE,
gels were dried, exposed to X-ray film and analyzed by
phosphoimaging.
Binding assay: surface plasmon resonance (SPR) analysis
Binding of purified AP-2 and recombinant A2 (residues
157–434) to immobilized GST-Gag fusion proteins was
monitored by surface plasmon resonance. AP-2 was purified
from pig brain. A2 was purified from the E. coli strain BL21
transfected with the pET28a vector (Novagen) containing
N-terminally 6 His-tagged rat A2 (residues 158–9435) and
was a gift from V. Haucke (Free University Berlin,
Germany). Protein production was induced by addition of
IPTG for 3 h at 30 -C followed by purification of the A-
chain protein from 1 L of bacteria. The purification was
performed according to a standard protocol (Qiagen) using
Ni-NTA agarose as an affinity matrix (the complete protocol
is available upon request). The purity of the A2 which were
stored in 10 mM HEPES–KOH pH 7.4, 500 mM NaCl, 10
mM ß-mercaptoethanol was controlled by SDS–PAGE.
Before any SPR experiment, all proteins were centrifuged
30 min/100,000  g for removal of possible protein
aggregates.
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immobilized on all 4 flow-cells of a CM5 sensor-chip
resulting in shift of the baseline of 8.000 resonance units.
Variation in immobilization between flow-cells was less
than 4%. The running buffer was 10 mM HEPES–KOH pH
7.4 and contained 500 mM NaCl to minimize non-specific
electrostatic interactions with the negatively charged car-
boxymethylated sensor surface. The GST-Gag fusion
proteins were injected at equal concentrations at a flow rate
of 5 Al/min to allow capture by the anti-GST antibodies.
After capturing was saturated, AP-2 or A2 was injected at a
flow rate of 20 Al/min for 1 min at concentrations ranging
from 0.4 to 3 AM. Dissociation was monitored after
switching back to running buffer. The surface was regen-
erated by 3 consecutive pulse injections of 50 mM NaOH
for 5 s each. The determination of the rate constants was
calculated assuming a 1:1 first order kinetics after
subtraction of the binding of A to GST which was
regarded as background binding. The sensorgrams
shown in Fig. 1C are the original sensorgrams recorded
simultaneously on the 4 individual flow cells.
Release experiments
One million wild-type or mutant AP-2 cells were planted
in T25 flasks in tetracycline minus medium to induce
expression of either wild-type- or mutant-tagged A2, as
described (Nesterov et al., 1999). Three days later the cells
were transfected with 4 Ag of pGag-EGFP or pNL43 DNA.
The cells were labeled 24 h post-transfection with 100 ACi/
ml of Easy Tag Express 35S-Protein Labeling Mix (NEN) in
DMEM without Met and Cys (Invitrogen) and incubated at
37 -C for 12–16 h. The supernatant was removed and
filtered through a 0.45-Am filter followed by centrifugation
at 16,000  g for up to 90 min at 4 -C. The viral pellet was
resuspended in 30 Al of RIPA buffer (50 mM Tris–HCl pH
7.2, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate,
0.1% SDS) to which an equal volume of sample buffer was
added before boiling for 5 min at 100 -C. The cells were
lysed in RIPA buffer and centrifuged at 16,000  g for 90
min at 4 -C. To visualize cellular Gag-EGFP, the lysates
were immunoprecipitated by adding 4 Ag of anti-EGFP
antibody (Molecular Probes) and 50 Al of Protein G
sepharose (Pharmacia) to 100 Al of lysate and incubated
overnight at 4 -C. To visualize cellular HIV-1 Gag proteins,
the lysates were immunoprecipitated with a rabbit anti-CA
antibody (1:100; ABI) and 50 Al of protein A sepharose
(Pharmacia) and incubated overnight at 4 -C. The beads
were washed three times with RIPA and heated in 20 Al of
sample buffer for 5 min at 100 -C. The precipitates were
resolved by SDS–PAGE; gels were dried, exposed to X-ray
films, and analyzed by phosphoimager. Bands representing
uncleaved or partially cleaved Gag and thus contributing to
the Gag signal in either VLP/viral and cell lysates (i.e., p55,
p41) were included in the calculations throughout this
analysis.Infectivity experiments
AP-2-wild-type or -mutant cells were planted in T75
flasks. Tetracycline was removed from the media three days
before transfection with 12 Ag of pNL43 DNA. Released
virus was collected 48 h post-transfection and centrifuged
for 10 min at 805  g. The amount of p24 was quantified by
ELISA (NEN Perkin Elmer). The CD4-positive long
terminal repeat galactosidase-expressing HeLa (MAGI) cell
indicator line (Kimpton and Emerman, 1992) was obtained
from the AIDS Research and Reference Program, Division
of AIDS, National Institute of Allergy and Infectious
Diseases, and maintained in DMEM supplemented with
10% FBS, 100 U/ml of penicillin G sodium, 0.1 mg/ml of
streptomycin sulfate. Cells were seeded at a density of 1.6 
105 per well in a 6-well plate 24 h prior to infection.
Samples of virus were adsorbed to cells in the presence of
20 Ag/ml DEAE-dextran for 2 h at 37 -C prior to the
addition of 1 ml of medium. Following incubation for 48 h
at 37 -C, the cells were fixed and stained with 5-bromo-4-
chloro-3-indolyl-d-galactopyranoside (X-Gal) as previously
described (Kimpton and Emerman, 1992).
Protein profile of released virus
One million wild-type or mutant AP-2 cells were planted
in T25 flasks in tetracycline minus medium to induce
expression of either wild-type- or mutant-tagged A2. Three
days later the cells were transfected with 4 Ag of pNL43
DNA. Forty-eight hours post-transfection the supernatant
was centrifuged for 10 min at 805  g to clear cellular
debris. The virus was harvested by a 90-min centrifugation
at 16,000  g. The viral pellet was resuspended in 30 Al of
RIPA buffer to which 10 Al of 4 sample buffer was added
before boiling for 5 min at 100 -C. To visualize the viral
proteins, lysed virions were loaded onto a 10% SDS–PAGE
gel and transferred to nitrocellulose membrane (Bio-Rad).
The membrane was probed with a mixture of monoclonal
antibodies obtained from the AIDS Research and Reference
Program, a-p24 AG3.0 at 1:500 and a-gp120 at 1:500. A
secondary a-mouse antibody conjugated to HRP was used
at 1:2000. The amounts of virus-associated Gag and Env
were quantified by CCD Imager (Bio-Rad).
Immunocytochemistry, imaging analysis by fluorescence
microscopy
AP-2-wild-type and -mutant cells expressing pGag-EGFP
or pGagopt were grown on chambered coverslides (Lab-Tek).
The cells were washed with PBS and fixed with 3.7%
paraformaldehyde for 10 min and permeabilized with 0.2%
Triton X-100 for 10 min at room temperature. After blocking
with 1% BSA, the fixed cells were incubated in primary
antibody for 1 h at 37 -C, washed with PBS, blocked for 10
min in 1% BSA, and incubated in secondary antibody for 30
min at room temperature. The stained cells were washed with
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antibodies and serum were used; undiluted AP-6 supernatant
(ATCC), rabbit p6Gag antiserum (AIDS Vaccine Program,
NCI Fredrick, Frederick, MD). The following secondary
antibodies were used; anti-mouse Texas red-conjugated
antibodies (Jackson ImmunoResearch, West Grove, PA),
anti-mouse, or anti-rabbit antibodies conjugated to either
AlexaFluor 488, 594, or 647 (Molecular Probes).
To obtain high-resolution images of the cells, a DeltaVi-
sion imaging workstation consisting of a high resolution
CCD CH350 camera (Kodak KAF1401E, Full Frame Chip)
and a Nikon inverted wide-field fluorescence microscope
equipped with a z-step motor (Applied Precision, Inc.) was
used. EGFP and AlexaFluor 488 were detected using a
standard FITC filter set, Texas red and AlexaFluor 594
fluorescence were detected using a standard rhodamine/
Texas red filter set.
For quantification of Gag–AP-2 colocalization described
in Fig. 5, ten pictures of cells expressing Gagopt (Rudner et
al., 2005) with either wild-type or mutant AP-2 were taken.
0.2-Am z-stacks from the bottom of each cell were imaged
and deconvolved using the constrained iteration method on
the DeltaVision software. Using the DeltaVision software,
SoftWoRx, the bottom z-stack of each cell was chosen for
further analysis. Gag–AP-2 colocalization was quantified
using Volocity (Improvision) colocalization software.Acknowledgments
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